Publications

5891 Results

Validation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG

Authors
M. Othus
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #2656 poster
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers and Melanoma
Study Number(s)
S1404, S1609

Long non-coding RNA (lncRNA) SNHG11 as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC): Insights from CALGB (Alliance)/SWOG 80405

Authors
M. Bartolini
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #3128 poster
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Small nucleolar RNAs (snoRNAs) expression and effects on patient (pt) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB (Alliance)/SWOG 80405

Authors
F. Battaglin
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #3145 poster
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Abstract 2787: Effect of miR-494 modulation in colorectal cancer (CRC): Clinical outcome, target expression and cell characteristics

Authors
Pooja Mittal;Joshua Millstein;Shivani Soni;Francesca Battaglin;Karam Ashouri;Sandra Algaze;Priya Jayachandran;Yan Yang;Lesly T. Gonzalez;Unnati H. Shah;Wu Zhang;Fang-Shu Ou;Alan P. Venook;Indrakant K. Singh;Heinz J. Lenz
Journal / Conference
AACR 2025; Journal: Cancer Research, Cancer Res (2025) 85 (8_Supplement_1): 2787
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

IMPACT OF EBV STATUS AND HISTOLOGY ON OUTCOMES WITH NIVOLUMAB-AVD VERSUS Bv-AVD IN PATIENTS ENROLLED ON SWOG S1826

Authors
S. Ahmed;H. Li;A. F Herrera;A. Perry;A. E Kovach;K. Davison;S. C Rutherford;S. Castellino;A. Evens;B. Kahl;N. Bartlett;J. P Leonard;M. A Shipp;S. M Smith;K. Kelly;M. LeBlanc;J. W Friedberg;J. Y Song
Journal / Conference
ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025), e20_70093
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1826

HEALTH-RELATED QUALITY OF LIFE (HRQoL) ENDPOINTS OF THE PHASE III INTERGROUP S1826 ADVANCED-STAGE, CLASSIC HODGKIN LYMPHOMA (cHL) TRIAL

Authors
J. M. Unger;H. Li;A. F. Herrera;K. Davison;S. M. Castellino;H. Dillon;T. Hernandez;S. C. Rutherford;A. Punnett;M. LeBlanc;J. Y. Song;S. M. Smith;A. M. Evens;K. M. Kelly;J. W. Friedberg;S. K. Parsons
Journal / Conference
ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025), e127_70093
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1826

THE ASSOCIATION OF SOCIAL DISADVANTAGE WITH OUTCOMES IN PATIENTS WITH ADVANCED-STAGE, CLASSIC HODGKIN LYMPHOMA ENROLLED IN THE PHASE 3 INTERGROUP TRIAL S1826

Authors
J. M. Kahn;J. M. Unger;H. Li;S. M. Castellino;H. Dillon;T. Hernandez;S. C. Rutherford;A. Punnett;M. LeBlanc;J. Y. Song;S. M. Smith;A. M. Evens;K. M. Kelly;J. W. Friedberg;A. Herrera
Journal / Conference
ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025), e368_70093
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1826

S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24)

Authors
P. M. Barr;H. Li;H. Schoder;A. F. Herrera;W. R. Burack;B. K. Link;C. R. Flowers;O. Weigert;C. Casulo;T. Siddiqi;P. Venugopal;J. P. Leonard;B. S. Kahl;S. M. Smith;J. W. Friedberg
Journal / Conference
ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025), e233_70093
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1608

LONG-TERM FOLLOW-UP OF AN INTENSIVE PEDIATRIC REGMEN FOR ADOLESCENTS/YOUNG ADULTS (AYA) WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): 10-YEAR SURVIVAL FOLLOWING CALGB 10403 (ALLIANCE)

Authors
A. Advani;Wendy Stock;Jun Yin;Michaela Liedtke;David Claxton;Noreen Fulton;Sharmila Giri;Greg Malnassy;Krzysztof Mrozek;Elizabeth Paietta;Charles Mullighan;Richard Larson;Geoffrey Uy;Selina Luger
Journal / Conference
Euro Hem Assoc mtg June 2025, #S118
Year
2025
Research Committee(s)
Leukemia
Study Number(s)
C10403

Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609)

Authors
Ahluwalia MS
Journal / Conference
Clin Cancer Res. 2025 Dec 11. doi: 10.1158/1078-0432.CCR-25-2900. Online ahead of print.
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID41378983
Study Number(s)
S1609